Article Figures & Data
Figures
- Figure 1.
Relationship between months of treatment with SERM and AI and OR of RA incidence. Statistically significant at *** p < 0.001. SERM: selective estrogen receptor modulator; AI: aromatase inhibitor; RA: rheumatoid arthritis.
- Figure 2.
Relationship between months of treatment with SERM and AI and OR of SLE incidence. Statistically significant at ** p < 0.01, *** p < 0.001. SERM: selective estrogen receptor modulator; AI: aromatase inhibitor; SLE: systemic lupus erythematosus.
Tables
RA SLE Drug Mos of Treatment Total Patients N Rate, % OR (95% CI) N Rate, % OR (95% CI) None 0 190,620 4460 2.34 1.00 (ref) 1330 0.70 1.00 (ref) SERM 2–11 11,180 330 2.95 1.26*** (1.13–1.41) 110 0.98 1.41*** (1.16–1.71) 12+ 1420 80 5.63 2.41*** (1.92–3.02) 20 1.41 2.02** (1.29–3.15) AI 2–11 20,420 630 3.09 1.32*** (1.21–1.44) 120 0.59 0.84 (0.70–1.02) 12+ 3700 160 4.32 1.85*** (1.57–2.17) 20 0.54 0.77 (0.50–1.21) Cohort Patients in Cohort Patients with SLE SLE Prevalence Patients with RA RA Prevalence All women 18+ yrs 12,087,760 46,590 0.39% 117,580 0.97% Patients with breast cancer 238,880 1660 0.69% 5920 2.48% -
RA: rheumatoid arthritis; SLE: systemic lupus erythematosus.
-
In this issue
The Effect of Antiestrogen Agents on Risk of Autoimmune Disorders in Patients with Breast Cancer
